• Mashup Score: 1

    October 13, 2023 — Arineta Cardiac Imaging is excited to announce the FDA 510(k) clearance of the SpotLight and SpotLight Duo family of cardiovascular CT (CCT) scanners. The two products extend Arineta’s leadership as the only dedicated cardiovascular CT system, and the Duo system adds high resolution thoracic clinical capability, including for lung cancer, COVID19, and other pulmonary diseases. Both the SpotLight and SpotLight Duo systems add extended coverage for peripheral vascular and runoff studies, a rapidly growing procedure for vascular therapies.   “Arineta has been the leader in cardiovascular CT technology, and the new SpotLight systems continue Arineta’s history of clinical innovation,” said Scott Schubert, Arineta CEO. “Our vision is to grow cardiac CT as the front-line non-invasive test for diagnosing, therapy planning and monitoring of cardiovascular disease- the number one cause of death and costs for healthcare worldwide.”  “The recent change in guidelines from the ACC

    Tweet Tweets with this article
    • @DAICeditor @ArinetaCardio #Arineta #CardiacImaging announced the #FDA 510(k) clearance of the #SpotLight and #SpotLightDuo family of #cardiovascular #CT (#CCT) scanners: https://t.co/Qj3RE4Th7Z

  • Mashup Score: 0

    Appropriate use criteria that have been certified by CMS for coronary artery disease imaging are heterogeneous and, at times, discrepant, according to a review recently published in Annals of Internal Medicine. The 2014 Protecting Access to Medicare Act established the Appropriate Use Criteria (AUC) Program to reduce unnecessary advanced imaging studies, David E. Winchester, MD, MS, an associate

    Tweet Tweets with this article
    • 🏥 A new review found #CMS-approved appropriate use criteria for #cardiacimaging may cause confusion among clinicians. David Shumway, DO, from @AOAforDOs said "the article highlights serious issues ... that need to be addressed promptly." 🔗 Read more: https://t.co/K5F9kaG0jI

  • Mashup Score: 0

    July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has been granted FDA clearance for its AI-powered ultrasound guidance technology. The UltraSight real-time AI guidance software can assist medical professionals without sonography experience in acquiring cardiac ultrasound images at the point of care in multiple settings, allowing for more widespread detection of heart disease and providing patients easier access to cardiac monitoring.  With more than 8 million patients admitted to U.S. emergency departments every year with symptoms concerning for heart attack or heart failure according to the Centers for Disease Control and Prevention, access to timely and accurate cardiac ultrasound in the acute care setting can save lives. In addition, approximately 30 million heart disease patients in the U.S. continue to require periodic cardiac monitoring. However, significant bottlenecks within the U.S.

    Tweet Tweets with this article
    • @DAICeditor @UltraSightAI New #AI guidance software will allow more #medical professionals to conduct #cardiac #ultrasound in multiple care settings expanding patient access to #cardiacimaging: https://t.co/T6k5ZqSHhP